LI
ESPR

Leap Investments’s Esperion Therapeutics ESPR Stock Holding History

Leap Investments’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$210K Buy
+4,100
New +$172K 0.14% 287

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Leap Investments's ESPR Position: Q2 2020 in Review

Leap Investments opened a new position in Esperion Therapeutics (ESPR) in Q2 2020: 4,100 shares worth $210K. The stake represents 0.14% of the portfolio and ranks #287 among its holdings.

182 funds tracked by Wall St. Rank hold ESPR as of Q2 2020.

  • Leap Investments held 4,100 shares of Esperion Therapeutics worth $210K as of Q2 2020.
  • Esperion Therapeutics was a new Leap Investments position in Q2 2020.
  • Esperion Therapeutics made up 0.14% of Leap Investments's portfolio in Q2 2020, its #287 holding.
  • 182 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.